Cargando…
Clinical outcomes of mild to moderate coronavirus disease 2019 patients treated with Regdanvimab in delta-variant outbreak: Retrospective cohort study
Regdanvimab is a novel neutralizing antibody agent used for the treatment of coronavirus disease 2019 (COVID-19). However, the effectiveness of regdanvimab in delta-variant patients has rarely been investigated. We examined the clinical outcomes and adverse events in COVID 19 patients treated with r...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637437/ https://www.ncbi.nlm.nih.gov/pubmed/37960790 http://dx.doi.org/10.1097/MD.0000000000035987 |
_version_ | 1785146502798114816 |
---|---|
author | Noh, Hyeong-Jun Song, Jin Hwa Ham, Sin Young Park, Yeonkyung Won, Ha-Kyeong Kim, Soo Jung Chung, Keun Bum Kim, Choon Kwan Ahn, Young Mee Lee, Byoung-Jun Kang, Hye-Rin |
author_facet | Noh, Hyeong-Jun Song, Jin Hwa Ham, Sin Young Park, Yeonkyung Won, Ha-Kyeong Kim, Soo Jung Chung, Keun Bum Kim, Choon Kwan Ahn, Young Mee Lee, Byoung-Jun Kang, Hye-Rin |
author_sort | Noh, Hyeong-Jun |
collection | PubMed |
description | Regdanvimab is a novel neutralizing antibody agent used for the treatment of coronavirus disease 2019 (COVID-19). However, the effectiveness of regdanvimab in delta-variant patients has rarely been investigated. We examined the clinical outcomes and adverse events in COVID 19 patients treated with regdanvimab in the delta-variant era. Data were collected from laboratory-confirmed COVID-19 hospitalized patients who received regdanvimab in 2021 and categorized into pre-delta and delta variant groups. The primary outcome was the need for oxygen therapy. Rescue therapy, clinical improvement, and adverse events were analyzed. Among 101 patients treated with regdanvimab, 31 (30.7%) were delta patients and 49 (48.5) were pre-delta patients. 64.4% were male, the mean age was 60.3 years, and 70 patients (69%) had at least one underlying disease. The median interval from symptom onset to injection was 4 days. Twenty-three patients (23%) needed oxygen therapy, including 9 (29%) in the delta and 8 (16.3%) in the pre-delta group. (P = .176) The risk of early oxygen supplement was higher in the delta group (adjusted hazard ratio (aHR), 6.75; 95% confidence interval(CI), 1.53–29.8). The in-hospital survival rate was 100%, and no patients were admitted to the intensive care unit. Adverse events occurred in 43% of patients:13 (42%) delta patients and 23 (47%) pre-delta patients had any adverse events (P = .661). Patients treated with regdanvimab 4 days after symptom onset showed a favorable prognosis (aHR, 0.26; 95% CI, 0.26–0.91). We found that the high-risk mild to moderate COVID-19 patients treated with regdanvimab showed similar disease progression in delta-variant patients and pre-delta variants; however, we need to be more closely observed delta-variant patients than those in the pre-delta group despite regdanvimab treatment due to rapid disease aggravation. |
format | Online Article Text |
id | pubmed-10637437 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-106374372023-11-15 Clinical outcomes of mild to moderate coronavirus disease 2019 patients treated with Regdanvimab in delta-variant outbreak: Retrospective cohort study Noh, Hyeong-Jun Song, Jin Hwa Ham, Sin Young Park, Yeonkyung Won, Ha-Kyeong Kim, Soo Jung Chung, Keun Bum Kim, Choon Kwan Ahn, Young Mee Lee, Byoung-Jun Kang, Hye-Rin Medicine (Baltimore) 6700 Regdanvimab is a novel neutralizing antibody agent used for the treatment of coronavirus disease 2019 (COVID-19). However, the effectiveness of regdanvimab in delta-variant patients has rarely been investigated. We examined the clinical outcomes and adverse events in COVID 19 patients treated with regdanvimab in the delta-variant era. Data were collected from laboratory-confirmed COVID-19 hospitalized patients who received regdanvimab in 2021 and categorized into pre-delta and delta variant groups. The primary outcome was the need for oxygen therapy. Rescue therapy, clinical improvement, and adverse events were analyzed. Among 101 patients treated with regdanvimab, 31 (30.7%) were delta patients and 49 (48.5) were pre-delta patients. 64.4% were male, the mean age was 60.3 years, and 70 patients (69%) had at least one underlying disease. The median interval from symptom onset to injection was 4 days. Twenty-three patients (23%) needed oxygen therapy, including 9 (29%) in the delta and 8 (16.3%) in the pre-delta group. (P = .176) The risk of early oxygen supplement was higher in the delta group (adjusted hazard ratio (aHR), 6.75; 95% confidence interval(CI), 1.53–29.8). The in-hospital survival rate was 100%, and no patients were admitted to the intensive care unit. Adverse events occurred in 43% of patients:13 (42%) delta patients and 23 (47%) pre-delta patients had any adverse events (P = .661). Patients treated with regdanvimab 4 days after symptom onset showed a favorable prognosis (aHR, 0.26; 95% CI, 0.26–0.91). We found that the high-risk mild to moderate COVID-19 patients treated with regdanvimab showed similar disease progression in delta-variant patients and pre-delta variants; however, we need to be more closely observed delta-variant patients than those in the pre-delta group despite regdanvimab treatment due to rapid disease aggravation. Lippincott Williams & Wilkins 2023-11-10 /pmc/articles/PMC10637437/ /pubmed/37960790 http://dx.doi.org/10.1097/MD.0000000000035987 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | 6700 Noh, Hyeong-Jun Song, Jin Hwa Ham, Sin Young Park, Yeonkyung Won, Ha-Kyeong Kim, Soo Jung Chung, Keun Bum Kim, Choon Kwan Ahn, Young Mee Lee, Byoung-Jun Kang, Hye-Rin Clinical outcomes of mild to moderate coronavirus disease 2019 patients treated with Regdanvimab in delta-variant outbreak: Retrospective cohort study |
title | Clinical outcomes of mild to moderate coronavirus disease 2019 patients treated with Regdanvimab in delta-variant outbreak: Retrospective cohort study |
title_full | Clinical outcomes of mild to moderate coronavirus disease 2019 patients treated with Regdanvimab in delta-variant outbreak: Retrospective cohort study |
title_fullStr | Clinical outcomes of mild to moderate coronavirus disease 2019 patients treated with Regdanvimab in delta-variant outbreak: Retrospective cohort study |
title_full_unstemmed | Clinical outcomes of mild to moderate coronavirus disease 2019 patients treated with Regdanvimab in delta-variant outbreak: Retrospective cohort study |
title_short | Clinical outcomes of mild to moderate coronavirus disease 2019 patients treated with Regdanvimab in delta-variant outbreak: Retrospective cohort study |
title_sort | clinical outcomes of mild to moderate coronavirus disease 2019 patients treated with regdanvimab in delta-variant outbreak: retrospective cohort study |
topic | 6700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637437/ https://www.ncbi.nlm.nih.gov/pubmed/37960790 http://dx.doi.org/10.1097/MD.0000000000035987 |
work_keys_str_mv | AT nohhyeongjun clinicaloutcomesofmildtomoderatecoronavirusdisease2019patientstreatedwithregdanvimabindeltavariantoutbreakretrospectivecohortstudy AT songjinhwa clinicaloutcomesofmildtomoderatecoronavirusdisease2019patientstreatedwithregdanvimabindeltavariantoutbreakretrospectivecohortstudy AT hamsinyoung clinicaloutcomesofmildtomoderatecoronavirusdisease2019patientstreatedwithregdanvimabindeltavariantoutbreakretrospectivecohortstudy AT parkyeonkyung clinicaloutcomesofmildtomoderatecoronavirusdisease2019patientstreatedwithregdanvimabindeltavariantoutbreakretrospectivecohortstudy AT wonhakyeong clinicaloutcomesofmildtomoderatecoronavirusdisease2019patientstreatedwithregdanvimabindeltavariantoutbreakretrospectivecohortstudy AT kimsoojung clinicaloutcomesofmildtomoderatecoronavirusdisease2019patientstreatedwithregdanvimabindeltavariantoutbreakretrospectivecohortstudy AT chungkeunbum clinicaloutcomesofmildtomoderatecoronavirusdisease2019patientstreatedwithregdanvimabindeltavariantoutbreakretrospectivecohortstudy AT kimchoonkwan clinicaloutcomesofmildtomoderatecoronavirusdisease2019patientstreatedwithregdanvimabindeltavariantoutbreakretrospectivecohortstudy AT ahnyoungmee clinicaloutcomesofmildtomoderatecoronavirusdisease2019patientstreatedwithregdanvimabindeltavariantoutbreakretrospectivecohortstudy AT leebyoungjun clinicaloutcomesofmildtomoderatecoronavirusdisease2019patientstreatedwithregdanvimabindeltavariantoutbreakretrospectivecohortstudy AT kanghyerin clinicaloutcomesofmildtomoderatecoronavirusdisease2019patientstreatedwithregdanvimabindeltavariantoutbreakretrospectivecohortstudy |